Metabolomics as a potential method for predicting thyroid malignancy in children and adolescents

Zhou, Qing; Zhang, Liyong; Xie, Chao; Zhang, Mei-Lian; Wang, Yunjin; Liu, Guanghua

doi:10.1007/s00383-019-04584-0

Cited by 13 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, with the aim of avoiding the invasive biopsy of the thyroid, there have also been studies that looked for associations between thyroid malignancies and plasma [50,56,70,83] or serum metabolites [52,72,79,84,85]. A study of children and adolescents with thyroid cancer identified an increase in the levels of serum leucine, lactate, alanine, lysine, acetate, glycine and choline and lower levels of glucose in papillary thyroid carcinoma samples versus benign by 1 H NMR spectroscopy, which is consistent with other works in adults [86]. More recently, a plasma GC-MS study has suggested sucrose as a discriminative compound between papillary thyroid cancer and multinodular goitre, which poses an interesting question as to the influence of high sucrose sugar diets in the promotion of tumorigenesis [83].…”

Section: Peripheral Fluidssupporting

confidence: 82%

The Potential of Metabolomics in the Diagnosis of Thyroid Cancer

Coelho

Raposo

Goodfellow

et al. 2020

IJMS

View full text Add to dashboard Cite

Thyroid cancer is the most common endocrine system malignancy. However, there is still a lack of reliable and specific markers for the detection and staging of this disease. Fine needle aspiration biopsy is the current gold standard for diagnosis of thyroid cancer, but drawbacks to this technique include indeterminate results or an inability to discriminate different carcinomas, thereby requiring additional surgical procedures to obtain a final diagnosis. It is, therefore, necessary to seek more reliable markers to complement and improve current methods. “Omics” approaches have gained much attention in the last decade in the field of biomarker discovery for diagnostic and prognostic characterisation of various pathophysiological conditions. Metabolomics, in particular, has the potential to identify molecular markers of thyroid cancer and identify novel metabolic profiles of the disease, which can, in turn, help in the classification of pathological conditions and lead to a more personalised therapy, assisting in the diagnosis and in the prediction of cancer behaviour. This review considers the current results in thyroid cancer biomarker research with a focus on metabolomics.

show abstract

Section: Peripheral Fluidssupporting

confidence: 82%

The Potential of Metabolomics in the Diagnosis of Thyroid Cancer

Coelho

Raposo

Goodfellow

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Of note, the de novo biosynthesis of serine/glycine, is a process that is activated in highly glycolytic cancer cells and the expression rates of the serine/ glycine metabolism-related proteins have been found to differ among various thyroid cancers, being higher in papillary thyroid carcinomas and poorly differentiated carcinomas 38 . Recently, the role of glycine (and lactate) as the potential serum marker of papillary thyroid carcinoma has been confirmed in children and adolescents 40 . However, our results indicate that alterations of the metabolism of these amino-acids are not specific to malignant lesions but are also observed in the benign ones.…”

Section: Discussionmentioning

confidence: 99%

Shared and unique metabolic features of the malignant and benign thyroid lesions determined with use of 1H HR MAS NMR spectroscopy

Skorupa

Ciszek

Chmielik

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The purpose of this work was to investigate the distinct and common metabolic features of the malignant and benign thyroid lesions in reference to the non-transformed tissue from the contralateral gland (chronic thyroiditis and colloid goiter). 1H HR MAS NMR spectra of 38 malignant lesions, 32 benign lesions and 112 samples from the non-tumoral tissue (32 from chronic thyroiditis and 80 samples from colloid goiter) were subjected both to multivariate and univariate analysis. The increased succinate, glutamine, glutathione, serine/cysteine, ascorbate, lactate, taurine, threonine, glycine, phosphocholine/glycerophosphocholine and decreased lipids were found in both lesion types in comparison to either colloid goiter or chronic thyroiditis. The elevated glutamate and choline, and reduced citrate and glucose were additionally evident in these lesions in reference to goiter, while the increased myo-inositol—in comparison to thyroiditis. The malignant lesions were characterized by the higher alanine and lysine levels than colloid goiter and thyroiditis, while scyllo-inositol was uniquely increased in the benign lesions (not in cancer) in comparison to both non-tumoral tissue types. Moreover, the benign lesions presented with the unique increase of choline in reference to thyroiditis (not observed in the cancerous tissue). The metabolic heterogeneity of the non-tumoral tissue should be considered in the analysis of metabolic reprogramming in the thyroid lesions.

show abstract

“…In the present study, a decreased glucose level and increased lactate level in the LN-negative and LNpositive PTC groups compared to those in the healthy control group indicated that the energy supply pattern shifted from aerobic to anaerobic metabolism (Figure 4) (26,29). Creatine, phosphocreatine, and creatinine, through the creatine kinase reaction, played important roles in maintaining a constant ATP level (32).…”

Section: Discussionmentioning

confidence: 57%

“…The presence of LN in patients with PTC was also distinguished for the first time, where no clear associations was observed. Compared with the published reports of the metabolic profiling of PTC (26)(27)(28)(29), we focused on the metabolite profiling of whole blood in investigations of human health and PTC patients. The identified metabolites may be the potential factors for the diagnosis and prognosis of PTC patients.…”

Section: Discussionmentioning

confidence: 99%

Diagnosis of papillary thyroid carcinoma by <sup>1</sup>H NMR spectroscopy-based metabolomic analysis of whole blood

Wang

et al. 2020

DD&T

View full text Add to dashboard Cite

Thyroid, 1 H NMR spectroscopy, metabolomics, lymph node metastasis, papillary thyroid carcinoma The incidence rate of thyroid carcinoma, especially papillary thyroid carcinoma (PTC), has increased significantly over time. As a primary pathway for metastasis, the lymphatic system is an important prognostic factor for PTC patients. Although the metabolic changes in PTC patients have been investigated in extensive studies, few studies focused on the whole blood metabolic profiling of PTC patients. In this study, we investigated the 1 H NMR-based metabolic profiles of whole blood samples that were obtained from healthy individuals and PTC patients, with or without lymph node metastasis. The estimation of the predictive potential of metabolites was evaluated using multivariate statistical analyses, which revealed that the whole blood carries information that is sufficient for distinguishing between PTC patients and healthy individuals. However, PTC patients were not well classified as positive or negative according to the lymph nodes. We did not find a metabolite that could discriminate the presence of lymph node metastasis. Further studies with larger sample sizes are needed to elucidate significant metabolites to indicate the presence of lymph node metastasis in patients with PTC.

show abstract

Metabolomics as a potential method for predicting thyroid malignancy in children and adolescents

Cited by 13 publications

References 25 publications

The Potential of Metabolomics in the Diagnosis of Thyroid Cancer

The Potential of Metabolomics in the Diagnosis of Thyroid Cancer

Shared and unique metabolic features of the malignant and benign thyroid lesions determined with use of 1H HR MAS NMR spectroscopy

Diagnosis of papillary thyroid carcinoma by <sup>1</sup>H NMR spectroscopy-based metabolomic analysis of whole blood

Contact Info

Product

Resources

About